News and Press Releases

  • May 23, 2016
  • ALS Patients from Around the World Responding Well to Genervon's GM604
  • Good results without adverse effects reported by doctors and ALS patients
  • Read More
  • May 19, 2016
  • Genervon Case Report Update from International ALS Patients
  • Genervon Biopharmaceuticals has continued to provide GM604 to Doctors of named ALS patients around the world since our December 10, 2015 Press Release.
  • Read More
  • May 3, 2016
  • GM604 to Be Granted "Orphan Drug" Status in Europe
  • Genervon Biopharmaceuticals today announced that its very promising ALS treatment has successfully passed the EM'?s "COMP" phase. The Committee for Orphan Medicinal Products (COMP) has issued a positive opinion...
  • Read More
  • April 29, 2016
  • Updated Genervon Science & GM604
  • Genervon has received many inquiries from ALS patients, caregivers and doctors requesting the access of GM604. The following updated summary is an attempt to answer some of their questions
  • Read More
  • December 10, 2015
  • Genervon Case Report Summary from International ALS Patients treated by GM604
  • Pasadena, CA - 12/10/15 5:00AM PST While our colleagues are gathering at the ALS International Symposium in Orlando Florida, Genervon is overwhelmed by many deserving ALS patients' requests to access GM604 now to save their lives...
  • Read More
  • September 22, 2015
  • Genervon GM604 Reduced TDP-43 Protein Aggregates and Slowed Down ALS Progression
  • PASADENA, Calif. Researchers and clinicians have long recognized that ALS is a heterogeneous neurodegenerative disease. Recently scientists are beginning to understand why that is the case. One of the major pathological ...
  • Read More
  • June 29, 2015
  • Genervon filed patent for using GM604 modulations of ALS disease biomarkers showing homeostasis, leading to prognosis and therapeutic treatment for ALS disease
  • PASADENA, Calif. Genervon Biopharmaceuticals ("Genervon") today announced that its lawyers have filed patent for legal protection of its intellectual properties based on the proprietary data from its Phase 2A clinical trial with GM604 f...
  • Read More
  • April 17, 2015
  • Update on FDA Progress
  • Genervon is aware of FDA's request for the public release of additional data from its clinical investigations of GM604 in the treatment of ALS, and Genervon is reviewing that request...
  • Read More
  • March 21, 2015
  • Update for ALS Patients and Caregivers who have contacted Genervon
  • Dear ALS patients and caregivers, after our February meeting with the FDA, we have filed a formal request for the Accelerated Approval (AA) Program and are now waiting for a final decision.
  • Read More
  • February 16, 2015
  • Genervon Biopharmaceuticals reviews results of phase 2a als trial; awaits fda response
  • Genervon is a privately held California biopharmaceutical company that was founded by Winston and Dorothy Ko, who were inspired by the Biblical prophecy that "the lame will leap like a deer, and the mute tongue shout for joy"...
  • Read More
  • February 5, 2015
  • For A.L.S. Patients, a Hopeful Drug That Is Out of Reach
  • After the height of the Ice Bucket Challenge last fall, I found myself at a dinner party where the conversation turned to A.L.S. - amyotrophic lateral sclerosis - the disease for which millions were dousing themselves to raise awareness and money...
  • Read More
  • April 29, 2014
  • Genervon Successfully Completes its Phase 2a Clinical Trial for ALS
  • Genervon Biopharmaceuticals LLC ("Genervon") today announced that it has successfully completed its Phase 2a clinical trial for amyotrophic lateral sclerosis ("ALS") disease modification...
  • Read More
  • March 02, 2014
  • FDA Grants "Orphan Drug" Designation for Genervon's Breakthrough Multi-Target ALS Bio-Drug GM604
  • Genervon Biopharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted an "orphan drug" designation to Genervon's GM604 (a.k.a. GM6) bio-drug for the treatment of Amyotrophic Lateral Sclerosis (ALS)...
  • Read More
  • June 26, 2013
  • FDA Granted Fast Track Designation for Genervon's Breakthrough Biotechnology Multi-Target ALS Drug GM604 Expediting Drug Approval Process
  • In a huge victory for ALS sufferers, FDA granted Genervon Biopharmaceuticals a fast track designation for its first in class highly effective multi-target master regulator biotechnology drug GM604 for ALS. FDA said it met the necessary criteria...
  • Read More
  • June 3, 2013
  • FDA Approves Broadly Inclusive Phase IIa ALS Clinical Trial with GM604, a Biotechnology Innovation
  • Offering imminent hope for those with ALS, Genervon Biopharmaceuticals, an innovative biotechnology company announced today that it has received FDA approval and is now recruiting patients for its broadly inclusive ALS clinical trial...
  • Read More
  • May 20, 2013
  • Multiple Target ALS Drug Ready for Genervon's Phase 2 Trial
  • Multiple targets, highly effective, breakthrough therapy for ALS sufferers may now be within reach. Winston Ko, the CEO of Genervon Biopharmaceuticals, will be presenting on Friday at the Neurotech Conference in San Francisco that its endogenous regulatory drug GM604 modulates over 80 ALS related gene targets interactively and dynamically through 12 pathways and up to 22 biological processes, including neurogenesis, neural development, signaling and transport...
  • Read More
  • January 4, 2013
  • Genervon will present at Biotech Showcase? Mechanisms of Actions of GM604 on 30 ALS genes
  • Genervon Biopharmaceuticals, LLC, a clinical stage biopharmaceutical company focused on neurodegenerative diseases, announced today that President and CEO, Winston Ko will present at the Biotech Showcase? 2013 Conference being held in San Francisco on 1/08/13 Tuesday 10:45AM...
  • Read More
  • December 17, 2012
  • European Patent Office Issues Its Intention to Grant Genervon Biopharmaceuticals a European Patent on Methods of Treating Neuronal Disorders Using MNTF Peptides and Analogs Thereof
  • The European Patent Office notified Genervon of its intention to grant a European patent on Methods of Treating Neuronal Disorders using MNTF peptides and analogs thereof. Genervon will proceed to have the patents for EPO application No. 07867451.2 issued, bringing the portfolio of Genervon's issued Composition of Matters and Use patents to 46.
  • Read More
  • December 12, 2012
  • Genervon established that it's targeted drug benefits ALS disorder through 8 pathways and modulates over 30 specific ALS genes dynamically
  • Genervon scientists have confirmed that the target of GM604 regulates over 4,000 genes. More significantly, it modifies ALS progression by modulating at least 30 significant ALS related genes. It does this through at least 8 pathways, potentially more, and up to 22 biological processes...
  • Read More
  • February 23, 2012
  • Genervon to Award Price for Scientists Proposing Medical Indications and Trial Protocols - Genervon GrandChallenges (G2C)
  • Genervon Biopharmaceuticals, LLC, a clinical stage biopharmaceutical company, proposes multiple grand challenges to provide biological drugs to meet many unmet critical medical needs of the world...
  • Read More

 

 


 
Copyright © 2016 Genervon Biopharmaceuticals, LLC. All rights reserved. All other trademarks or trade names are the property of their respective holders.